Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 2/20 | 0.54 |
| ▸ | RXRB | P28702 | 2/20 | 0.54 |
| ▸ | RXRG | P48443 | 2/20 | 0.54 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | FFAR1 | O14842 | 4/20 | 0.48 |
| ▸ | CTSK | P43235 | 1/20 | 0.47 |
| ▸ | FFAR4 | Q5NUL3 | 5/20 | 0.46 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.46 |
| ▸ | BRD4 | O60885 | 1/20 | 0.43 |
| ▸ | IP6K1 | Q92551 | 1/20 | 0.42 |
| ▸ | IP6K3 | Q96PC2 | 1/20 | 0.42 |
| ▸ | IP6K2 | Q9UHH9 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27936782 | 0.88 | GPBAR1 (0.53) | RXRARXRBRXRGGPBAR1MAPT | |
| SCHEMBL5775556 | 0.85 | MAPT (0.56) | GPBAR1MAPTFFAR1FFAR4GABRA5 | |
| SCHEMBL13733019 | 0.79 | GPBAR1 (0.64) | GPBAR1MAPTBRD4IP6K1IP6K3 | |
| SCHEMBL4029417 | 0.77 | GPBAR1 (0.53) | GPBAR1MAPTBRD4IP6K1IP6K3 | |
| SCHEMBL10833017 | 0.77 | RXRA (0.59) | RXRARXRBRXRGFFAR1CTSK | |
| SCHEMBL27918229 | 0.76 | BRD4 (0.50) | RXRARXRBRXRGGPBAR1FFAR1 | |
| SCHEMBL27936779 | 0.74 | GPBAR1 (0.55) | GPBAR1MAPTBRD4IP6K1IP6K3 | |
| SCHEMBL11420447 | 0.74 | GPBAR1 (0.61) | GPBAR1MAPT | |
| SCHEMBL13734246 | 0.74 | GPBAR1 (0.61) | GPBAR1MAPT | |
| SCHEMBL5772667 | 0.74 | FFAR4 (0.65) | RXRARXRBRXRGGPBAR1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060084690-A1 | Isoxazole derivatives | MOMOSE YU | 2006-04-20 | — | — | US | disclosed |
| US-7022725-B2 | Isoxazole derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-04-04 | — | — | US | disclosed |
| US-20040048908-A1 | Isoxazole derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-03-11 | — | — | US | disclosed |
| EP-1340749-A1 | ISOXAZOLE DERIVATIVES | Takeda Chemical Industries, Ltd. (JP) | 2003-09-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060084690-A1 | Isoxazole derivatives | INSR, GPR119, INSRR | RXRA 445/4885RXRB 494/4885RXRG 503/4885 |
| US-20040048908-A1 | Isoxazole derivatives | GPR119, INSR, IRS1 | RXRA 462/4885RXRB 550/4885RXRG 628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.